Drug intelligence / Profile preview

PMR-116

Development stage: Unknown
Lead developer: Pimera
Modality: Small Molecules
Administration: Oral

Overview

**PMR-116 is a small molecule, second-generation inhibitor of RNA polymerase I (Pol I) transcription, developed for the treatment of various cancers, particularly those driven by MYC oncogene overexpression. It acts by inhibiting ribosomal RNA synthesis downstream of MYC, thereby disrupting protein synthesis essential for tumor growth. PMR-116 is being developed primarily for advanced solid tumors and hematological malignancies. The drug has shown promising preclinical results in reducing cancer lesions and slowing tumor growth in MYC-driven cancers.**

Other names: PMR-116PMR116PMR 116

Targets

Pol I (RNA polymerase I)

Beyond the preview

Go deeper on PMR-116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMR-116.

Explore the full profile